The hypotensive effect of tripamide(Normonal(R)) were evaluated in 31 cases of essential hypertension. Fifteen to thirty mg of tripamide per day were administered continuously for 8 weeks. The results were as follows; 1) The systolic blood pressure was significantly lowered from 175+/-15 mmHg(Mean+/-SD) before treatment to 144+/-17 mmHg after treatment(p<0.01), and the diastolic blood pressure was significantly lowered from 106+/-11 mmHg before treatment to 90+/-12 mmHg after treatment(p<0.01). 2) The systolic blood pressure was lowered 20 mmHg or more in 25 out of 31 cases(80.7%), and the diastolic blood pressure was decreased 10 mmHg or more in 25 out of 31 cases(80.7%) at the end of 8 weeks treatement. 3) There was no significantl differences in the level of SGOT, serum cholesterol, serum electrolytes(Na+, K+, Cl-), BUN, creatinine and urinc acid before and after treatment with tripamide. 4) In most cases the subjective symptoms disappeared or became easier after tripamide treatment. 5) Profound weakness was developed in 2 cases during tripamide administration.
Aspartate Aminotransferases ; Blood Pressure ; Cholesterol ; Creatinine ; Hypertension*

The antihypertensive effect of Doxazocin were evaluated in 20 patients with essential hypertension. Two to eight mg of Doxazocin per day were administered continuously for two or eight weeks. The results were as follows : 1) Doxazocin were effective in 18 out of 20 patients(90%) at the end of 8 weeks treatment. 2) The systolic blood pressure was signigicantly decreased(173+/-20mmHg VS 144+/-33mmHg, P+/-0.001), and the diastolic blood pressure was also decreased(110+/-10mmHg VS 93+/-19mmHg, P<0.01) after treatment. 3) Triglyceride showed a decreasing tendency but statistically significance was not observed. Total cholesteral, HDL-cholesterol, BUN, creatinine, and uric acid did not change significantly before and after treatment with Doxazocin. 4) The side effects were headache in one case and dizziness in to cases. These results suggest that Doxazocin is an effective antihypertensive agent and concerning lipid profile, further long term observation is needed.
Blood Pressure ; Creatinine ; Dizziness ; Headache ; Humans ; Hypertension* ; Triglycerides ; Uric Acid

In order to evaluate the peritoneal transport characteristics in Korean non-diabetic and diabetic end- stage renal disease patients, peritoneal equilibration test(PET) proposed by Twardowski et al. were performed on patients who had been on continuous ambulatory peritoneal dialysis(CAPD) for 2 to 6 months. The results were as follows : 1) Fifty four patients(including 24 diabetics) on CAPD were studied with a mean age of 48.7 years. And male/female ratio was 1 : 1.08. 2) In non-diabetics, the dialysate to dialysate prior to infusion ratio for glucose(D/D0 glu) at 2-, and 4-hour dwell times were 0.61+/-0.09, and 0.39+/-0.10, and the dialysate-to-plasma ratio for creatinine (D/P cr) at 2-, and 4-hour dwell times were 0.40+/-0.11, 0.63+/-0.12, respectively. 3) In diabetic patients, D/D0 glu at 2-, and 4- hour dwell times were 0.60+/-0.09, 0.39+/-0.08, respectively, and D/P cr at same dwell times were 0.50+/-0.08, and 0.71+/-0.08, which were significantly higher than in non-diabetics(p<0.05). 4) According to the two-hour plasma glucose concentration, diabetic patients were subdivided into hyperglycemic(>or=150mg/dL) and normoglycemic(<150mg/ dL) patients. The values of D/Pcr at 2-, and 4-hour dwell times in hyper-glycemic patients were signficantly higher than in non-diabetic patients (D2/P2 cr : 0.50+/-0.09 vs. 0.40+/-0.11, D4/P4 cr : 0.72+/-0.07 vs 0.63+/-0.12, respectively, p<0.05). 5) Net ultrafiltration did not differ between any of subgroups. 6) In non-diabetic patients, the ranges of D4/P4 cr and D4/D0 glu for high, high average, low average, and low transporters were defined as D4/P4 cr : 0.87-0.75, 0.75-0.63, 0.63-0.51, 0.51-0.39, D4/D0 glu : 0.19-0.29 0.29-0.39, 0.39-0.49, 0.49-0.59, respectively, which were remarkably simliar as suggested by Twardowski et al. In conclusion, the creatinine and glucose transfers assessed by dialysate-plasma ratio of creatinine and glucose are remarkably similar between Korean and North American patients. And the creatinine transport rate in Korean diabetic patient is higher than non-diabetic patient while ultrafiltration is achievable in non-diabetic patient.
Blood Glucose ; Creatinine ; Glucose ; Humans ; Peritoneal Dialysis, Continuous Ambulatory* ; Ultrafiltration

BACKGROUND: Routine renal function tests are not sensitive enough to detect early renal complication of diabetes. To detect the complication as soon as possible, we measured urine N-Acetyl-beta-D-glucosaminidase(NAG) and evaluated in comparison with microalbumin and beta2-microglobulin(beta2-MG). METHODS: 87 patients with type II diabetes visited Catholic University Hospital of Taegu Hyosung during the period October 1995 to March 1996. We collected 24 hour urine samples and measured NAG, albumin excretion rate (AER), beta2-MG. urinalysis, BUN, creatinine(Cr) Cr clearance(CrCl), fasting and 2 hour postprandial blood sugar and hemoglobin A1c. RESULTS: The average age of the patients was 53+/-15 years old and their average disease duration was 5.8+/-5.0 years. Abnormal rates of each renal function tests were as follows : NAG/gCr 52.1%, AER 51.7%, CrCl 42.5%, BUN 18.4%, beta2-MG 13.8% and creatinine 6.9% in order. From 36 patients whose AER was within normal limit, 13 of them(36.1%) showed increased level of NAG/gCr. Of 38 patients with increased NAG/gCr results, the 31 patients (81.6%) recorded abnormal results of renal function tests. Among 87 patients studied 60 patients(68.5%) showed increased level of NAG/gCr or AER results. Compared with AER test alone. the combined tests with NAG/gCr increased 16.8% of detection rates of renal complication in type II diabetes. CONCLUSION: Urine NAG/gCr and AER tests were very useful for detecting the early renal complication of type n diabetes. As increase of NAG/gCr suggest the proximal tubule damage, it is necessary to have further evaluation about the proximal tubule damage of renal complication in type II diabetes.
Acetylglucosaminidase* ; Blood Glucose ; Creatinine ; Daegu ; Fasting ; Humans ; Urinalysis

BACKGROUNDSerum creatinine (Scr) measurement plays a key role in glomerular filtration rate estimation (eGFR), chronic kidney disease (CKD) diagnosis as well as CKD treatment. However, the test results of Scr from different laboratories vary significantly. In order to get comparable results, the European in vitro diagnostic (IVD) directive requires traceability to reference methods and materials. The purpose of this study was to verify the effect of traceability implementation by investigating the trueness of creatinine measurement on nine homogenous systems in Beijing.

METHODSCommutable frozen human serum reference material, National Institute of Standards & Technology (NIST) Standard Reference Material (SRM) 967, was used to verify the trueness of Scr measurement results from nine homogeneous analytical systems of seven companies which are the most widely used systems in Beijing's third-grade hospitals. The methods referred to the Jaffe's and Enzymatic methods.

RESULTSfrom nine routine measurement systems were assessed using two criteria: biological variability and Clinical Laboratory Improvement Amendments' 88 (CLIA' 88). We simulated a series of broken lines representing the limits of SD and bias that would produce a relative increase (or decrease) of 10% and 20% in the measurement error when estimating GFR (MEeGFR) using the isotope dilution mass spectrometry (IDMS)-traceable Modification of Diet in Renal Disease (MDRD) Study equation.

RESULTSof the College of American Pathologists (CAP) 2008-B LN24 Survey were compared with our investigation results.

RESULTSCompared with the total error criteria of biological variability, Ortho (traceable to IDMS) met the minimum acceptable criteria; Roche (Jaffe), Roche (Enzymatic), Shino and Daiichi met the desirable criteria at level I. At level II, Ortho (traceable to gas chromatography/isotope dilution mass spectrometry, GC/IDMS), Dade Behring and Beckman (traceable to rate Jaffe) met the minimum acceptable criteria; Roche (Enzymatic) met the optimum criteria. The other five systems met the desirable criteria. Compared with the second criterion, all the results met the requirement of CLIA' 88. Trueness evaluation showed: the MEeGFR of Dade Behring exceeded 10% while the MEeGFRs of Beckman (traceable to rate Jaffe), Beckman (traceable to IDMS) and Ortho (traceable to Jaffe/High Performance Liquid Chromatography) exceeded 20% at level I. At level II the MEeGFRs of Dade Behring, Ortho (traceable to GC/IDMS) and Beckman (traceable to rate Jaffe) exceeded 10%. None of the nine systems got a MEeGFR higher than 20%. The conclusions of NIST SRM 967 agreed with those of LN 24 except for the Beckman measurement system.

CONCLUSIONSTrueness investigation of routine creatinine assays on nine homogeneous systems demonstrates an encouraging outcome that meets clinical requirements. Among the nine homogeneous routine systems, Roche and Daiichi produce the most accurate results. The implementation of traceability is effective.

Renal blood flow was measured by single injection technique of HippuranI13 in 13 patients with chronic glomerulonephritis and 11 control subjects. There was a significant decrease in renal blood flow in chronic glomerulonephritis particulary in those with elevated blood urea nitrogen. Renal blood flow was inversely proportionate to renal vascular resistance but no correlation was noted between renal blood flow and creatinine clearance.
Blood Urea Nitrogen ; Creatinine ; Glomerulonephritis* ; Humans ; Renal Circulation* ; Vascular Resistance

OBJECTIVE: The objective of this study is to assess whether the patients with dysphagia, who must take fluid thickener and dysphagia diet, have adequate fluid and calory intake. METHOD: Fifteen patients with dysphagia were participated in this study. In all of them, dysphagia was documented by videofluoroscopy and viscosity modification was recommended. The amount of fluid and calory intake was measured for 3 consecutive days during taking thickened fluid and dysphagia diet. serum sodium, blood urea nitrogen (BUN) and creatinine (Cr) level were measured. RESULTS: Fourteen of 15 patients with dysphagia took adequate fluid and calory. In thirteen of 14 patients, BUN/Cr ratio and serum sodium were within normal limit. In one of 14 patients, BUN/Cr ratio was elevated due to excessive protein intake. One of 15 patients with dysphagia took the fluid and calory under the standard. Her BUN/Cr ratio was 27.2. But this patient took more fluid and nutrition day after day. At 3rd day after measurement, she took adequate fluid and calory. CONCLUSION: Sufficient fluid and calory could be supplied with fluid thickener and dysphagia diet. But physician should observe carefully whether dysphagic patient consume adequate amount of fluid and calory.
Blood Urea Nitrogen ; Creatinine ; Deglutition Disorders* ; Diet ; Humans ; Sodium ; Viscosity

The clinical trial was carried out with Bunazosin in 31 patients with essential hypertension. The results were as follows : 1) Before and after 1, 2, 4, 6, and 8 weeks of medications, the overall average systolic and distolic blood pressure were 166.5+/-21.8/105.7+/-10.6, 152.7+/-17.2/99.8+/-11.1, 149.5+/-18.1/98.4+/-11.7, 148.5+/-16.9/97.3+/-11.3, 148.5+/-16.7/95.6+/-10.9 and 144.0+/-14.9/94.2+/-11.1mmHg. As a result, blood pressure significantly fell within 1week of medication, and marked and moderate degree of hypetensive effect was observed within 8weeks og medication in 45% of all cases. 2) Before and after 1, 2, 4, 6, and 8weeks of medication, the overall average heart rates were 79.7+/-10.1, 78.3+/-9.1, 79.4+/-7.4, 80.8+/-8.3, 79.2+/-8.9 and 80.1+/-8.3 beats/minute. There were no significant change in heart rates before and after medication. 3) There were no significant changes in values of complete blood counts, GOT, GDT, blood urea nitrogen, serum creatinine and total cholesterol before and after medication. On the basis of these results, we observed that Bunazosin was effective hypertensive drug.
Blood Cell Count ; Blood Pressure ; Blood Urea Nitrogen ; Cholesterol ; Creatinine ; Heart Rate ; Humans ; Hypertension

BACKGROUND: Cyclosporin A (CsA), a potent immunosuppressant, has been reported to be effective in the treatment of severe atopic dermatitis (AD). OBJECTIVE: The aim of this study was to evaluate the efficacy and side-effects of CsA in Korean patients with severe AD. MATERIALS AND METHODS: 16 patients with recalcitrant AD took CsA for at least 6 weeks. Among them, 11 patients were followed up for more than 16 weeks. Initial dose was 5mg/kg/day (maximum 300 mg/day) and the dose was reduced according to their therapeutic responses. SCORAD (Scoring AD) was used to evaluate clinical efficacy of CsA. During the 1st month of therapy, the therapeutic efficacy and side-effects were evaluated every 2weeks and after 1 month, every month. We checked blood pressure and laboratory abnormalities including liver function test, blood urea nitrogen (BUN), creatinine (Cr) and urinalysis at each visit in addition to observing clinical adverse effects. RESULTS: Significant reduction of SCORAD was noted in 15 patients after 6 weeks of CsA therapy. Only one patient stopped CsA therapy because of the elevation of blood pressure. Three patients showed albuminuria, which disappeared after CsA dose reduction. CONCLUSION: CsA can be used effectively and safely in severe Korean AD patients. Albuminuria seems to be a peculiar side-effect in Korean patients.
Albuminuria ; Blood Pressure ; Blood Urea Nitrogen ; Creatinine ; Cyclosporine* ; Dermatitis, Atopic* ; Humans ; Liver Function Tests ; Urinalysis

Arotinolol, a new alpha and beta receptor antagonist, was administered in 27 essential hypertensive patients for 8 weeks in order to evaluate the antihypertensive effect and side effects. The dose were 10mg to 15mg given twice a day. The results are as follows : 1) Before medication, systolic and diastolic blood pressure in sitting, supine and erect position were 173.1+/-3.2/105.8+/-1.8, 171.1+/-3.6/86.7+/-2.0 and 169.3+/-2.6/97.2+/-2.1mmHg. 2) After 8 weeks treatment moderated to marked antihypertensive effect was observed in 74.0%(in systolic blood pressure) and 81.4%(in diastolic blood pressure) respectively in sitting position. 3) There was a significant reduction of pulse rate from 73.0+/-2.5 beats per minute on the beginning of the treatment to 63.4+/-5.2 beats per minute after 8 weeks of medication. 4) There was no significant change in hematocrit, WBC, serum lipid, GOT, GPT, BUN and creatinine. But fasting blood sugar was reduced from 95.3mg% to 81.5mg% with treatment. 5) The side effects of arotinolol were gastrointestinal symptoms(15%), fatigue(11%), dizziness(7%) and insomnia(3%). But these side effects were not severe enough to discontinue medication. In summary, arotinolol seemed to be an effective antihypertensive drug in treating mild to moderate hypertension without significant side effects.
Blood Glucose ; Blood Pressure ; Creatinine ; Fasting ; Heart Rate ; Hematocrit ; Humans ; Hypertension